Abstract
The International Society of Nephrology has adopted a proactive approach to defining the current state of kidney care and unmet needs through a multifaceted Closing the Gaps initiative. As part of this initiative, the International Society of Nephrology convened a meeting of experts to develop an approach to tackle acute kidney injury and chronic kidney disease (CKD). This manuscript expands on the recently published International Society of Nephrology CKD Roadmap and reports on the discussions of the working group assigned to the task of reviewing the global impact of complication of CKD. The working group defined the following goals: Goal 1: Optimize the management of anemia and endocrine and metabolic abnormalities associated with CKD. The impact of these conditions at a global level is not well understood, particularly in regions where renal replacement therapy is not readily available. Some treatment regimens may be affordable in low- and middle-income countries and if implemented, could have an impact on the burden of suffering associated with CKD. Goal 2: Improve the prevention and management of cardiovascular complications linked to CKD. Most research on cardiovascular complications of CKD has focused on atherosclerotic diseases (myocardial infarction, ischemic stroke, and peripheral gangrene). There has been growing recognition that other forms of cardiovascular diseases, such as heart failure, valvular disease and arrhythmias, have a major impact on patient outcomes. Much less is known about the mechanisms and treatment of these non-atherosclerotic complications. Goal 3: Improve the diagnosis and management of symptoms associated with CKD. Symptom management is one of the greatest challenges in the management of CKD, with limited knowledge about the mechanisms associated with the development of these common problems and how best to characterize them into usable clinical phenotypes. Improved understanding of the complications of CKD may alleviate suffering and prolong life among millions of people worldwide both in developed countries and in regions where renal replacement therapy is not widely available.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 122-129 |
| Number of pages | 8 |
| Journal | Kidney International Supplements |
| Volume | 7 |
| Issue number | 2 |
| DOIs | |
| State | Published - Oct 1 2017 |
Fingerprint
Keywords
- CKD
- complications
- knowledge gaps
- management
- mechanisms
ASJC Scopus subject areas
- Nephrology
Cite this
Complications of chronic kidney disease : current state, knowledge gaps, and strategy for action. / Bello, Aminu K.; Alrukhaimi, Mona; Ashuntantang, Gloria E.; Basnet, Shakti; Rotter, Ricardo C.; Douthat, Walter G.; Kazancioglu, Rumeyza; Köttgen, Anna; Nangaku, Masaomi; Powe, Neil R.; White, Sarah L.; Wheeler, David C.; Moe, Orson.
In: Kidney International Supplements, Vol. 7, No. 2, 01.10.2017, p. 122-129.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Complications of chronic kidney disease
T2 - current state, knowledge gaps, and strategy for action
AU - Bello, Aminu K.
AU - Alrukhaimi, Mona
AU - Ashuntantang, Gloria E.
AU - Basnet, Shakti
AU - Rotter, Ricardo C.
AU - Douthat, Walter G.
AU - Kazancioglu, Rumeyza
AU - Köttgen, Anna
AU - Nangaku, Masaomi
AU - Powe, Neil R.
AU - White, Sarah L.
AU - Wheeler, David C.
AU - Moe, Orson
PY - 2017/10/1
Y1 - 2017/10/1
N2 - The International Society of Nephrology has adopted a proactive approach to defining the current state of kidney care and unmet needs through a multifaceted Closing the Gaps initiative. As part of this initiative, the International Society of Nephrology convened a meeting of experts to develop an approach to tackle acute kidney injury and chronic kidney disease (CKD). This manuscript expands on the recently published International Society of Nephrology CKD Roadmap and reports on the discussions of the working group assigned to the task of reviewing the global impact of complication of CKD. The working group defined the following goals: Goal 1: Optimize the management of anemia and endocrine and metabolic abnormalities associated with CKD. The impact of these conditions at a global level is not well understood, particularly in regions where renal replacement therapy is not readily available. Some treatment regimens may be affordable in low- and middle-income countries and if implemented, could have an impact on the burden of suffering associated with CKD. Goal 2: Improve the prevention and management of cardiovascular complications linked to CKD. Most research on cardiovascular complications of CKD has focused on atherosclerotic diseases (myocardial infarction, ischemic stroke, and peripheral gangrene). There has been growing recognition that other forms of cardiovascular diseases, such as heart failure, valvular disease and arrhythmias, have a major impact on patient outcomes. Much less is known about the mechanisms and treatment of these non-atherosclerotic complications. Goal 3: Improve the diagnosis and management of symptoms associated with CKD. Symptom management is one of the greatest challenges in the management of CKD, with limited knowledge about the mechanisms associated with the development of these common problems and how best to characterize them into usable clinical phenotypes. Improved understanding of the complications of CKD may alleviate suffering and prolong life among millions of people worldwide both in developed countries and in regions where renal replacement therapy is not widely available.
AB - The International Society of Nephrology has adopted a proactive approach to defining the current state of kidney care and unmet needs through a multifaceted Closing the Gaps initiative. As part of this initiative, the International Society of Nephrology convened a meeting of experts to develop an approach to tackle acute kidney injury and chronic kidney disease (CKD). This manuscript expands on the recently published International Society of Nephrology CKD Roadmap and reports on the discussions of the working group assigned to the task of reviewing the global impact of complication of CKD. The working group defined the following goals: Goal 1: Optimize the management of anemia and endocrine and metabolic abnormalities associated with CKD. The impact of these conditions at a global level is not well understood, particularly in regions where renal replacement therapy is not readily available. Some treatment regimens may be affordable in low- and middle-income countries and if implemented, could have an impact on the burden of suffering associated with CKD. Goal 2: Improve the prevention and management of cardiovascular complications linked to CKD. Most research on cardiovascular complications of CKD has focused on atherosclerotic diseases (myocardial infarction, ischemic stroke, and peripheral gangrene). There has been growing recognition that other forms of cardiovascular diseases, such as heart failure, valvular disease and arrhythmias, have a major impact on patient outcomes. Much less is known about the mechanisms and treatment of these non-atherosclerotic complications. Goal 3: Improve the diagnosis and management of symptoms associated with CKD. Symptom management is one of the greatest challenges in the management of CKD, with limited knowledge about the mechanisms associated with the development of these common problems and how best to characterize them into usable clinical phenotypes. Improved understanding of the complications of CKD may alleviate suffering and prolong life among millions of people worldwide both in developed countries and in regions where renal replacement therapy is not widely available.
KW - CKD
KW - complications
KW - knowledge gaps
KW - management
KW - mechanisms
UR - http://www.scopus.com/inward/record.url?scp=85031733984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031733984&partnerID=8YFLogxK
U2 - 10.1016/j.kisu.2017.07.007
DO - 10.1016/j.kisu.2017.07.007
M3 - Review article
C2 - 30675426
AN - SCOPUS:85031733984
VL - 7
SP - 122
EP - 129
JO - Kidney International Supplements
JF - Kidney International Supplements
SN - 2157-1724
IS - 2
ER -